Abstracts

• Pathogenetic mechanisms in B-cell lymphomagenesis

  Davide Rossi, Daniela Capello, Gianluca Gaidano

  https://doi.org/10.4081/hmr.v1i5.243

  296

  PDF: 1055

  • PDF

• Epstein-Barr virus associated lymphomas

  Eva Klein

  https://doi.org/10.4081/hmr.v1i5.244

  240

  Untitled: 0

  PDF: 320

  • PDF

• Immunosuppression and lymphomagenesis

  Amy Chadburn

  https://doi.org/10.4081/hmr.v1i5.245

  245

  Untitled: 0

  PDF: 177

  • PDF

• The role of Epstein-Barr virus infection in human malignancies

  Lawrence S. Young

  https://doi.org/10.4081/hmr.v1i5.246

  262

  PDF: 465

  • PDF

• Alteration of B cell function by Epstein-Barr virus

  Ralf Küppers

  https://doi.org/10.4081/hmr.v1i5.247

  512

  PDF: 542

  • PDF

• Pathology of Epstein-Barr virus-related lymphomas in HIV

  Luigi Maria Larocca

  https://doi.org/10.4081/hmr.v1i5.248

  738

  PDF: 781

  • PDF

• Molecular pathology of post-transplant lymphoproliferative disorders

  Daniela Capello, Michaela Cerri, Davide Rossi, Eva Berra, Clara Deambrogi, Silvia Franceschetti, Chiara Vendramin, Lorenzo De Paoli, Valeria Primon, Cecilia Rus, Tamara Destro, Annarita Conconi, Gianluca Gaidano

  https://doi.org/10.4081/hmr.v1i5.249

  569

  Untitled: 0

  PDF: 396

  • PDF

• Treatment of Epstein-Barr virus-associated lymphomas: the role of Epstein-Barr virus-specific cytotoxic T cells

  Helen E Heslop, Catherine Bollard, Stephen Gottschalk, Barbara Savoldo, Malcolm K Brenne, Cliona M Rooney

  https://doi.org/10.4081/hmr.v1i5.250

  241

  Untitled: 0

  PDF: 359

  • PDF

• Treatment of ebv-associated lymphomas in hiv

  Andrea Antinori, Lucia Fratino

  https://doi.org/10.4081/hmr.v1i5.252

  349

  Untitled: 0

  PDF: 335

  • PDF

• New drugs and new types immunosuppression

  Robin Foà

  https://doi.org/10.4081/hmr.v1i5.253

  242

  PDF: 185

  • PDF

• New diagnostic tools

  Maurizio Sanguinetti

  https://doi.org/10.4081/hmr.v1i5.254

  294

  PDF: 403

  Untitled: 0

  • PDF

• Opportunistic infections in HIV-related lymphoma

  Antonella Cingolani

  https://doi.org/10.4081/hmr.v1i5.255

  221

  PDF: 594

  • PDF

• The use of purine analogues and infections

  Annamaria Nosari

  https://doi.org/10.4081/hmr.v1i5.256

  215

  Untitled: 0

  PDF: 839

  • PDF

• Monoclonal antibodies. How do they change the pattern of infections in lymphoproliferative diseases?

  B.E. de Pauw

  https://doi.org/10.4081/hmr.v1i5.257

  233

  Untitled: 0

  PDF: 178

  • PDF

• Diagnosis of hhv8 infection

  Paola Cattani

  https://doi.org/10.4081/hmr.v1i5.258

  323

  Untitled: 0

  PDF: 1721

  • PDF

• Kshv/hhv8-associated lymphomas

  Antonino Carbone

  https://doi.org/10.4081/hmr.v1i5.259

  246

  PDF: 372

  • PDF

• Hhv-8 infection and post-transplant malignancies

  Mario Luppi

  https://doi.org/10.4081/hmr.v1i5.260

  227

  Untitled: 0

  PDF: 333

  • PDF

• Alteration of B cell function by hepatitis C virus

  Shoshana Levy

  https://doi.org/10.4081/hmr.v1i5.261

  355

  PDF: 458

  • PDF

• Epidemiology of hepatitis C virus in lymphomas

  Alfonso Mele

  https://doi.org/10.4081/hmr.v1i5.262

  242

  PDF: 331

  • PDF

• Pathology of Helicobacter pylori-associated lymphomas

  Axel Greiner

  https://doi.org/10.4081/hmr.v1i5.263

  303

  PDF: 156

  • PDF

• Treatment of Helicobacter pylori-associated lymphomas

  Emanuele Zucca

  https://doi.org/10.4081/hmr.v1i5.264

  239

  Untitled: 0

  PDF: 270

  • PDF

• Immunoproliferative small intestinal disease associated with Campylobacter jejuni

  Marc Lecuit

  https://doi.org/10.4081/hmr.v1i5.265

  482

  PDF: 1380

  • PDF

• Chlamydia psittaci and ocular adnexal lymphomas

  Riccardo Dolcetti

  https://doi.org/10.4081/hmr.v1i5.266

  334

  Untitled: 0

  PDF: 347

  • PDF